Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Salix CEO Logan steps down following inventory misstep

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Salix CEO takes a hike in latest fallout from inventory snafu

On Monday afternoon, CEO Carolyn Logan became the second C-suite executive at Salix Pharmaceuticals to step down in the wake of an inventory snafu disclosed late last year. Logan will retire as of Jan. 30, the company said.

'Crown prince' Schultz not a sure bet for Novo CEO as Sørensen's contract nears end

With Novo Nordisk's chief exec Lars Rebien Sørensen's contract expiring within the next few years, the company's board is scouting his replacement. And as soon as they name one, Sørensen says he's ready to make a quick exit.

Scientist Andy Plump steps in at Takeda as R&D chief

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Sanofi's Plump tapped to head Takeda R&D from Cambridge base

The new president at Takeda has raided Sanofi for its new head of global R&D. And they're putting their new top scientist in Cambridge, MA, which is becoming the world headquarters of drug research for much of the pharma industry.

Broad's David Altshuler tapped as new CSO at Vertex

Today, Vertex announced that David Altshuler, the deputy director and chief academic officer of the legendary Broad Institute, will be the Boston biotech's new CSO, taking the place of the pioneering Peter Mueller.

Ex-Pfizer SVP takes the helm at BioClinica

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Small molecule chief named head of gRED in rejig at the top of Genentech

Having shepherded Genentech's R&D operations through the takeover by Roche, Richard Scheller will retire at the end of 2014. Roche has lined up Michael Varney, Genentech's head of small molecule drug discovery, to replace Scheller.

Pfizer tosses out HR rules with 'American Idol' recruiting in Sweden

Everyone who's ever applied for a job fears that recruiters will glance at their resumes and toss them out. Apparently, Pfizer's Swedish operation feared the same thing--and it tossed out the whole process.

Parnell shakes up management team, woos investors, as shares stagnate

In the midst of an ongoing campaign to boost its profile in the increasingly crowded animal health space, Parnell Pharmaceutical Holdings named two new top executives and one board member to its growing team on Tuesday evening. The Kansas company appointed veterinarian Edward Robb as chief scientific officer and Andy Ferrigno as vice president of global sales. Thomas E. Duley of life science consultancy King & Spalding was named to the company's board of directors.
'